Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUCE-SWEDEHEART: Beta-blockers after MI with preserved EF
NCT03278509Phase 4Active, not recruiting
- Sponsor
- Karolinska Institutet
- Start
- Sep 2017
- Primary completion
- Nov 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of metoprolol and bisoprolol in myocardial infarction (MI), sponsored by Karolinska Institutet. Primary endpoint: Composite of death of any cause or myocardial infarction at 3 years. Started Sep 2017; status: active, not recruiting.
02
Drugs
metoprololbisoprolol
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT03278509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03278509.